Deal-happy Sanofi to buy cancer-drug developer

In its second half-billion-dollar deal in a week, Sanofi-Aventis has agreed to buy the U.S. cancer drug specialist BiPar Sciences, aiming to build up its presence in biotech oncology meds. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.